 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Partners
Carmot has collaborations with academic and industry partners, including a research collaboration and licensing agreement with Amgen that was announced in 2014. Carmot and Amgen successfully applied Chemotype Evolution to identify novel binding sites and covalent inhibitors of KRASG12C, leading to the FDA approval and commercial launch of LUMAKRAS (sotorasib) in 2021. Carmot receives royalty payments on sales of LUMAKRAS.
Carmot also has a strategic partnership with Kimia Therapeutics to leverage the Chemotype Evolution (CE) discovery platform for metabolic diseases.
Carmot has a pipeline of drug candidates in metabolic diseases and is open to exploring new value-creating, strategic partnerships.
Contact Information: